Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CKD-337 in Healthy Male Volunteers
NCT03346187Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- May 2017
- Primary completion
- May 2017
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CKD-337 in dyslipidemia (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Atorvastatin Area Under the Curve to last measurable concentration, Atorvastatin Maximum Plasma Concentration and 2 more. Started May 2017; status: completed.
02
Drugs
CKD-337
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT03346187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03346187.